Arbele's ARB1002 Receives FDA Orphan Drug Designation
Arbele, a pioneering biotechnology company, has announced a significant achievement in its fight against pancreatic cancer. The U.S. Food and Drug Administration (FDA) has awarded its investigational antibody-drug conjugate (ADC), ARB1002, with Orphan Drug Designation. This milestone represents a hopeful advancement in developing targeted cancer therapies.
Understanding ARB1002 and Its Functionality
ARB1002 stands out as an innovative treatment composed of an anti-CDH17 monoclonal antibody linked to a potent cytotoxic agent. This unique structure allows the ADC to specifically target CDH17, a cell-surface adhesion molecule that is notably overexpressed in pancreatic cancer cells. By binding selectively to these cells, ARB1002 aims to deliver the cytotoxic component directly to tumor sites while minimizing damage to healthy tissue.
The Importance of Orphan Drug Designation
Receiving Orphan Drug Designation is crucial for Arbele and the patients it aims to serve. According to Dr Linda Wu, the Chief Development Officer at Arbele, this designation signifies a critical recognition of the urgent need for new treatment options for individuals battling pancreatic cancer. The FDA's program is tailored for diseases affecting less than 200,000 patients in the U.S., promoting incentivized development through potential tax benefits and market exclusivity.
Potential Impact on Patients and the Future of Treatment
Pancreatic cancer remains one of the most challenging solid tumors, notorious for its high mortality rate and limited effective treatments. The landscape of therapeutic intervention has remained stagnant, creating an urgent demand for innovative solutions such as ARB1002. As it moves into a Phase 1 clinical trial within the year, the ADC stands as a promising beacon of hope for those affected by this devastating condition.
Clinical Trials and Further Development
Arbele is currently finalizing the necessary IND-enabling studies that will support ARB1002's clinical evaluation. Dr Tony Wong, the Chief Technology Officer at Arbele, emphasized the significance of the FDA designation in validating the company’s approach to ADC development. Their expectation for continuing collaboration with the FDA emphasizes their commitment to advancing treatment options.
About Arbele: Pioneering Cancer Treatments
Arbele is not just stopping at ARB1002. The clinical-stage biotechnology company is on a mission to develop innovative therapies, including potential first-in-class and best-in-class immunotherapies targeting gastrointestinal cancers such as colorectal, gastric, and esophageal cancers. Their focus on CDH17-targeted treatments through T-cell engagers and ADCs underlines Arbele's aim to significantly enhance survival outcomes for patients facing high unmet medical needs.
For Inquiries
For press and business development inquiries, interested parties can reach out to Dr. Diana Hay for assistance. Arbele values collaboration and communication in its mission to transform cancer care.
Frequently Asked Questions
What is ARB1002?
ARB1002 is an investigational antibody-drug conjugate developed by Arbele for the treatment of pancreatic cancer.
What does Orphan Drug Designation mean?
It is a special status granted by the FDA to encourage the development of drugs for rare diseases, providing various incentives.
How does ARB1002 work?
ARB1002 works by targeting CDH17, allowing it to deliver a potent cytotoxic agent directly to pancreatic cancer cells, minimizing harm to healthy cells.
What stage is ARB1002 currently in?
ARB1002 is preparing to enter Phase 1 clinical trials, with studies underway to support this evaluation.
What is Arbele's goal?
Arbele aims to develop innovative therapies to improve survival outcomes for patients suffering from gastrointestinal cancers with significant unmet medical needs.
